← All trials
NCT03700749
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2018
- Primary completion
- Jul 31, 2021
- Completion date
- Jul 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 5480
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of BirminghamLead sponsor
- University of the WitwatersrandCollaborator
- University of BirminghamOverall official - principal investigator
- University of EdinburghCollaborator
- Cayetano Heredia UniversityCollaborator
- King Edward Medical UniversityCollaborator
- Christian Medical College, Vellore, IndiaCollaborator
- Lagos State UniversityCollaborator
- University of the PhilippinesCollaborator
- Universidad Francisco MarroquínCollaborator
- Tamale Teaching Hospital, TamaleCollaborator
- Ndola Teaching HospitalCollaborator
- Kigali Central University Hospital, RwandaCollaborator
- Hospital Espanol de VeracruzCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.